High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate

2.50
Hdl Handle:
http://hdl.handle.net/2336/93419
Title:
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate
Authors:
Gudjonsson, H; Bardhan, K D; Hoie, O; Kristensen, E S; Schuetz, E; Kliebe-Frisch, C; Pipkin, G A; Duggan, A E
Citation:
Aliment. Pharmacol. Ther. 1998, 12(11):1113-9
Issue Date:
1-Nov-1998
Abstract:
BACKGROUND: High Helicobacter pylori eradication rates have consistently been reported with 2-week dual therapy regimens of ranitidine bismuth citrate plus clarithromycin. Ranitidine bismuth citrate with two antibiotics may provide an alternative 1-week eradication regimen. METHODS: This double-blind, randomized, parallel group, international, multicentre study compared ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. for 2 weeks (RC) with ranitidine bismuth citrate 400 mg b.d., clarithromycin 500 mg b.d. and metronidazole 400 mg b.d. for 1 week (RCM) for eradication of H. pylori in 350 patients with dyspepsia. RESULTS: Treatment with RC and RCM eradicated H. pylori (established by the combination of two negative results from two discrete 13C-UBTs at nominal weeks 4 and 12) from 89% (95% CI: 84-94) and 92% (95% CI: 88-97) of the observed population, and from 78% (95% CI: 72-84) and 80% (95% CI: 75-86) of the intention-to-treat population. When established only by one negative 13C-UBT result at least 28 days after the end of treatment, the respective intention-to-treat rates were 85% (95% CI: 79-90) and 88% (95% CI: 83-93). Both regimens were well-tolerated, only 6% of patients given RC and 4% given RCM discontinued treatment. Median plasma bismuth concentrations at the end of the second week of study were low, at 3.5 and 0.4 ng/ mL, respectively. CONCLUSIONS: Ranitidine bismuth citrate triple therapy for 1 week (RCM) and dual therapy for 2 weeks (RC) were equally effective for the eradication of H. pylori infection.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1046/j.1365-2036.1998.00413.x

Full metadata record

DC FieldValue Language
dc.contributor.authorGudjonsson, Hen
dc.contributor.authorBardhan, K Den
dc.contributor.authorHoie, Oen
dc.contributor.authorKristensen, E Sen
dc.contributor.authorSchuetz, Een
dc.contributor.authorKliebe-Frisch, Cen
dc.contributor.authorPipkin, G Aen
dc.contributor.authorDuggan, A Een
dc.date.accessioned2010-03-02T15:00:41Z-
dc.date.available2010-03-02T15:00:41Z-
dc.date.issued1998-11-01-
dc.date.submitted2010-03-02-
dc.identifier.citationAliment. Pharmacol. Ther. 1998, 12(11):1113-9en
dc.identifier.issn0269-2813-
dc.identifier.pmid9845401-
dc.identifier.doi10.1046/j.1365-2036.1998.00413.x-
dc.identifier.urihttp://hdl.handle.net/2336/93419-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: High Helicobacter pylori eradication rates have consistently been reported with 2-week dual therapy regimens of ranitidine bismuth citrate plus clarithromycin. Ranitidine bismuth citrate with two antibiotics may provide an alternative 1-week eradication regimen. METHODS: This double-blind, randomized, parallel group, international, multicentre study compared ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. for 2 weeks (RC) with ranitidine bismuth citrate 400 mg b.d., clarithromycin 500 mg b.d. and metronidazole 400 mg b.d. for 1 week (RCM) for eradication of H. pylori in 350 patients with dyspepsia. RESULTS: Treatment with RC and RCM eradicated H. pylori (established by the combination of two negative results from two discrete 13C-UBTs at nominal weeks 4 and 12) from 89% (95% CI: 84-94) and 92% (95% CI: 88-97) of the observed population, and from 78% (95% CI: 72-84) and 80% (95% CI: 75-86) of the intention-to-treat population. When established only by one negative 13C-UBT result at least 28 days after the end of treatment, the respective intention-to-treat rates were 85% (95% CI: 79-90) and 88% (95% CI: 83-93). Both regimens were well-tolerated, only 6% of patients given RC and 4% given RCM discontinued treatment. Median plasma bismuth concentrations at the end of the second week of study were low, at 3.5 and 0.4 ng/ mL, respectively. CONCLUSIONS: Ranitidine bismuth citrate triple therapy for 1 week (RCM) and dual therapy for 2 weeks (RC) were equally effective for the eradication of H. pylori infection.en
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.relation.urlhttp://dx.doi.org/10.1046/j.1365-2036.1998.00413.xen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshAnti-Ulcer Agentsen
dc.subject.meshBismuthen
dc.subject.meshClarithromycinen
dc.subject.meshConfidence Intervalsen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshHelicobacter Infectionsen
dc.subject.meshHelicobacter pylorien
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMetronidazoleen
dc.subject.meshMiddle Ageden
dc.subject.meshRanitidineen
dc.titleHigh Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrateen
dc.typeArticleen
dc.contributor.departmentLandspitalinn, Reykjavik, Iceland.en
dc.identifier.journalAlimentary pharmacology & therapeuticsen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.